Gliotic Response and Reprogramming Potential of Human Müller Cell Line MIO-M1 Exposed to High Glucose and Glucose

Benedetta Russo1, Giorgia D'Addato2, Giulia Salvatore3

  • 1Unit of Endocrinology and Diabetology, Isola Tiberina-Gemelli Isola Hospital, 00186 Rome, Italy.

Insights

Human Müller glia cells (MGs) show distinct responses to diabetic conditions, with potential for reprogramming. Understanding these reactions is key to developing therapies for diabetic retinopathy and retinal neurodegeneration.

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Cell Biology

Background:

  • Diabetic retinopathy (DR) is a leading cause of vision loss, with retinal neurodegeneration (RN) as an early indicator.
  • Müller glia cells (MGs) are crucial for retinal health and respond to diabetic stress, exhibiting regenerative potential in lower vertebrates but reduced capacity in complex organisms.
  • The human Müller cell line (MIO-M1) serves as a model to study gliotic responses and reprogramming potential under diabetic conditions.

Purpose of the Study:

  • To investigate the gliotic response and reprogramming potential of human MIO-M1 cells under various glucose conditions mimicking diabetes.
  • To explore how sustained high-glucose and glucose fluctuation treatments affect MIO-M1 cell behavior.
  • To understand the differential responses of MIO-M1 cells based on their metabolic environment.

Main Methods:

  • Culturing human MIO-M1 cells in normoglycemic (5 mM glucose) and hyperglycemic (25 mM glucose) conditions.
  • Exposing cells to sustained high-glucose and glucose fluctuation treatments to simulate diabetic environments.
  • Analyzing the expression of glial fibrillary acidic protein (GFAP), Vimentin, SHH, and SOX2 to assess gliotic response and reprogramming potential.

Main Results:

  • MIO-M1 cells in normoglycemic conditions showed dynamic activation (gliotic response) with increased GFAP and Vimentin expression when exposed to high-glucose and glucose fluctuation.
  • Increased SHH and SOX2 expression were observed in normoglycemic cells, suggesting reprogramming potential.
  • Hyperglycemic MIO-M1 cells demonstrated adaptation/desensitization to sustained high-glucose and glucose fluctuation treatments.

Conclusions:

  • Human MIO-M1 cells exhibit differential responses to glucose treatments, influenced by the metabolic environment.
  • The study provides an in vitro model for exploring Müller glia cell responses in diabetes-associated retinal neurodegeneration.
  • Findings may inform future therapeutic strategies aimed at promoting neurogenesis and mitigating neurodegeneration in diabetic eyes.